Opinion

Video

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Ongoing Investigations: Expanding the Role of Cretostimogene in NMIBC Care
      Ongoing Investigations: Expanding the Role of Cretostimogene in NMIBC Care
      Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial
      Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial
      2 experts are featured in this series.
      Overcoming Challenges for Wider Adoption of TLX250
      1 expert is featured in this series.
      The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
      1 expert is featured in this series.
      Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability
      2 experts are featured in this series.
      Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Topline Data From the BOND-003 Trial in NMIBC
      Topline Data From the BOND-003 Trial in NMIBC
      1 expert is featured in this series.
      Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
      1 expert is featured in this series.
      A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
      Related Content
      Survey: New NMIBC treatments face slow uptake
      June 2nd 2025

      Survey: New NMIBC treatments face slow uptake

      Benjamin P. Saylor
      Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
      June 19th 2025

      Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

      Amy M. Pearlman, MD
      The conversation covers practical, case-based strategies for counseling MSM patients.
      Du Geon Moon, MD, PhD | Credit: Korea University College of Medicine
      April 27th 2025

      Sildenafil/Clomipramine Combo Boosts Outcomes in Premature Ejaculation

      Patrick Campbell
      A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.
      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
      June 2nd 2025

      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

      Amy M. Pearlman, MD
      Nathan Lawrentschuk, MBBS, PhD | Credit: Epworth Healthcare
      April 26th 2025

      ADAM, a long-term, injectable male birth control, shows promise at AUA 2025

      Patrick Campbell
      A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.
      Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
      April 26th 2025

      TikTok, social media does more harm than good for prostate cancer education

      Patrick Campbell
      Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
      © 2025 MJH Life Sciences

      All rights reserved.